Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 21, 2025Advanced ScienceOpen Access

Targeting the SOX9/TIMP1 Axis with iRGD‐Conjugated Nanoplatform Enhances Dendritic Cell Function and Photodynamic Immunotherapy in Gastric Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

BZBanghua ZhongYZYijie ZhangHWHonghu Wang

Discussion

Loading...

Member takes

Implication

The study demonstrates enhanced tumor growth suppression in gastric cancer by targeting SOX9, suggesting a novel immune-efficacy approach with dendritic cells and photodynamic immunotherapy.

Key Points

  • Dendritic cell maturation and antitumor immunity are improved by targeting SOX9 in gastric cancer.
  • Reactive oxygen species and nitric oxide generation contribute to the suppression of tumor growth and migration.
  • Photodynamic immunotherapy is enhanced through the use of iRGD-conjugated nanoparticles that deliver siSOX9 and chlorin e6.
  • Targeting the SOX9/TIMP1 axis reshapes the immunosuppressive microenvironment, promoting effective DC and T-cell activation.

Cite This Study

Zhong et al. (2025) studied this question.

synapsesocial.com/papers/6924e3ecc0ce034ddc34ee51https://doi.org/10.1002/advs.202510500
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Self-assembled nanoplatform for synergistic anti-angiogenic/photothermal therapy against gastric cancer with Src-mediated pathway blocking2026
  2. 2A Tumor Environment‐Activated Photosensitized Biomimetic Nanoplatform for Precise Photodynamic Immunotherapy of Colon Cancer2024 · 28 citations
  3. 3Enhancing gastric cancer immunotherapy: Insights from multi-omics analysis and innovations in photodynamic-chemotherapy nanoplatforms2026 · 2 citations
  4. 4Optimized Bionic Drug Delivery Inducing Immunogenic Cell Death and cGAS-STING Pathway Activation for Enhanced Photochemotherapy-Driven Immunotherapy in Prostate Cancer2024
  5. 5G‐Quadruplex‐Modular CpG Nanoplatform Drives Multi‐Pathway Immunity for Abscopal Chemoimmunotherapy2026 · 1 citations